+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies



Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies



American Journal of Medicine 123(7): S2-S10



This report highlights a roundtable discussion that occurred during the annual meeting of the International Diabetes Federation (IDF) in November 2009, in Montreal, Quebec, Canada. Participants included Bernard Zinman, MD, Michael A. Nauck, MD, PhD, Jorge Plutzky, MD, and Allison B. Goldfine, MD. The roundtable was chaired by Vivian A. Fonseca, MD. Among the topics discussed were the burden of type 2 diabetes mellitus and the importance of "appropriate therapy," which includes not only managing glycemia but also the management of concomitant risk factors such as hypertension and dyslipidemia. The discussants also identified issues that remain to be resolved, such as determining the nature of first-line therapy (e.g., should initial dual-agent therapy be encouraged?) and agreeing upon the most appropriate agent to be combined with metformin, which is the current standard of care. Among the new treatments discussed for type 2 diabetes were the analogues of the incretin hormones glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), namely, the GLP-1 receptor agonists-as well as the inhibitors of dipeptidyl peptidase-4 (DPP-4), the enzyme that regulates the bioactivity of the endogenous incretin hormones. These agents have some interesting advantages; not only do they effectively lower glucose, but they also have demonstrated beneficial metabolic and cardiovascular effects. Particularly with respect to the GIP and GLP-1, weight loss, blood pressure reductions, and beta-cell function improvements have been observed in clinical trials. What remains to be determined, by means of additional clinical experience and perhaps additional head-to-head trials, are the long-term benefits of GLP-1 receptor agonists and DPP-4 inhibitors and the sorts of roles these 2 classes of agents may play in the type 2 diabetes therapeutic continuum.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052294668

Download citation: RISBibTeXText

PMID: 20609666

DOI: 10.1016/j.amjmed.2010.04.002


Related references

Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and Dpp-4 Inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Emerging role of insulin with incretin therapies for management of type 2 diabetes. Diabetes Therapy 2(3): 146-161, 2011

Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Journal of the American Academy of Nurse Practitioners 20 Suppl 1: 7-11, 2009

The role of incretin-based therapies in the management of type 2 diabetes. Drug News and Perspectives 22(9): 559-567, 2010

Introduction: Evaluating the role of incretin-based therapies in the management of type 2 diabetes. American Journal of Managed Care 17(2 Suppl.): S39-S40, 2011

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clinical Therapeutics 33(5): 511-527, 2011

The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. Journal of Managed Care Pharmacy 13(9 Suppl C): S2-16; Quiz S17, 2008

Emerging incretin (glucagon-like peptide-1)-derived therapies for type 2 diabetes. Diabetes, Obesity and Metabolism 10(Suppl. S3): 1-1, 2008

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technology and Therapeutics 8(3): 385-396, 2006

Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira. Diabetic Medicine 33(7): 864-876, 2018

Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies. Journal of the American Osteopathic Association 114(5 Suppl 2): S6-13, 2015

Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies?. Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 319-324, 2013

Cardiac Protection via Metabolic Modulation An Emerging Role for Incretin-Based Therapies?. Cardiovascular & Hematological Agents in Medicinal Chemistry 10(4): 319-324, 2012